Neurology® Podcast

1) Fragile X premutation and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brandy Matthews interviews Dr. Kim Cornish about her paper on markers of at-risk profiles associated with the fragile X premutation. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about the "cookie test" for brachial plexus birth injury. In the next part of the podcast Dr. Brett Kissela interviews Dr. Bo Norrving about World Stroke Organization and state of stroke care around the world. Over the subsequent two weeks, Dr. Kissela will interview Drs. Mark Eckman and Tom Brott about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Matthews, Fugate, and Kissela.Dr. Brandy Matthews receives research support from the NIH.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke.

1) Functional psychogenic symptoms and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Michael Sharpe about his paper on guided self-help for functional (psychogenic) symptoms. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Melkersson-Rosenthal syndrome. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 2. Over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, Mark Eckman and Tom Brott about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Sharpe, Burns, Fugate, Kissela, Sacco and Goldstein.Dr. Sharpe serves as an Associate Editor for the Journal of Psychosomatic Research and on the editorial boards of General Hospital Psychiatry, Psychological Medicine, and Psychosomatics; serves as an independent medical advisor to AEGON Insurance; receives publishing royalties from Oxford University Press, Wiley-Blackwell and Churchill Livingstone and serves on a DSM5 work group for the American Psychiatric Association; is a member of Council of the Academy of Psychosomatic Medicine and receives research support from the Medical Research Council UK and Cancer Research UK.Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).

1) Duchenne muscular dystrophy and 2) Topic of the month: Stroke and stroke care. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Diana Escolar about her paper on weekend versus daily prednisone in Duchenne muscular dystrophy. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Guillain-Barre-like syndrome with thallium poisoning. In the next part of the podcast Dr. Brett Kissela interviews Drs. Ralph Sacco and Larry Goldstein about prevention of stroke part 1. Next week you will hear part 2 and over the subsequent three weeks, Dr. Kissela will interview Drs. Bo Norrving, about other aspects of stroke and stroke care. The participants had nothing to disclose except Drs. Escolar, Fugate, Kissela, Sacco and Goldstein.Dr. Escolar serves on a scientific advisory board for the NIH/NINDS; serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Athena Diagnostics, Inc.; has received speaker honoraria from Kennedy Krieger Institute and Acceleron Pharma; serves as a consultant for Gerson Lheman Group (GLC), Acceleron Pharma, and Medacorp; and receives research support from the NIH, the Muscular Dystrophy Association, and the Foundation to Erradicate Duchenne (FED).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Kissela has served on the scientific advisory board for for Allergan, Inc.; receives honoraria from Allergan, Inc; receives research support from the NIH; and gave expert testimony in medico legal cases related to stroke. Dr. Sacco serves on a data safety monitoring board indirectly sponsored by Pfizer Inc; serves on the editorial boards of Stroke and Neuroepidemiology; and receives research support from the NIH and the Evelyn McKnight Brain Institute. Dr. Goldstein is a consultant for Allergan, Inc. and Merck Serono; serves on the Steering Committee, SPARCL trial, is a consultant and speaker at meetings in which the SPARCL trial is discussed, Pfizer Inc serves on the Neurology Executive Committee, RESPECT Trial (AGA Medical) Clinical Oversight Committee, and ACT-1 trial (Abbott); and received research support from the RESPECT Trial Site (AGA Medical).

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2010-2011 academic year.

1) Cost-effectiveness of disease-modifying therapy and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan with Dr. Katia Noyes about her paper on disease-modifying therapy for multiple sclerosis. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about numb chin syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about peroneal neuropathy. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Keegan, Noyes, Fugate and Burns.Dr. Noyes serves on the scientific review panel for the National Multiple Sclerosis Society (NMSS) and has received research support from Biogen Idec, Boston Scientific, the NIH, and the NMSS.Dr. Keegan serves as a Section Editor for Neurology® and as Chief Editor for eMedicine; and has served as a consultant for Novartis and the FDA.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Exercise effect on Parkinson disease and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Morgan with Dr. Eric Ahlskog about his paper on vigorous exercise effect on Parkinson disease. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Beevor's sign. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about radial neuropathies. Next week, Dr. Burns will interview Dr. Stewart about another common mononeuropathy. The participants had nothing to disclose except Drs. Morgan, Ahlskog, Fugate and Burns.Dr. Morgan received research support from National Parkinson Foundation, Pharmaceutical Strategies Group, HealthCare Solutions Group, Merz Pharmaceuticals, LLC, NIH (NET-PD LS-1 [sub-investigator], Acadia Pharmaceuticals, Inc., Boehringer Ingelheim, EMD Serono, GlaxoSmithKline, and Solvay Pharmaceuticals Inc., serves on speakers' bureaus for Boehringer Ingelheim, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd. and National Parkinson Foundation, served as a consultant for Life Cycle Pharma, Lundbeck, National Parkinson Foundation, and Teva Pharmaceutical Industries Ltd.. Dr. Ahlskog received the Fred Springer Award from the American Parkinson's Disease Association; serves on the editorial boards of Parkinsonism and Related Disorders and Clinical Neuropharmacology; receives royalties from the publication of The Parkinson's Disease Treatment Book (Oxford University Press, 2005), Parkinson's Disease Treatment Guide for Physicians (Oxford University Press, 2009), Parkinson's Disease and Movement Disorders (Humana Press, 2000), and Surgical Treatment of Parkinson's Disease and Other Movement Disorders (Humana Press, 2003); and receives research support from NIH/NINDS.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Diagnosed multiple sclerosis and clinically isolated syndrome and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chris Scherer with Dr. Stine Marit Moen about her paper on newly diagnosed multiple sclerosis and clinically isolated syndrome.In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about hung-up reflex. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about ulnar neuropathies. Over the subsequent two weeks, Dr. Burns will interview Dr. Stewart about other common mononeuropathies. The participants had nothing to disclose except Drs. Moen, Fugate and Burns.Dr. Moen has received funding for travel from Biogen Idec; and has received research support from Biogen Idec, the South-Eastern Norway Regional Health Authority, Odd Fellow Research Foundation for Multiple Sclerosis, the Endowment of K. and K.H. Hemsen, and the Endowment of Fritz and Ingrid Nilsen.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Outcome of comatose patients and 2) Topic of the month: Mononeuropathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Flaherty interviews Dr. Eelco Wijdicks about his paper on predicting outcome of comatose patients. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about eight-and-a-half-syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. John Stewart about median neuropathies. Over the subsequent three weeks, Dr. Burns will interview Dr. Stewart about other common mononeuropathies. The participants had nothing to disclose except Drs. Flaherty, Wijdicks, Fugate and Burns.Dr. Flaherty is a consultant for Boehringer Ingelheim, received research support from PhotoThera, Inc. and is funding by NIH grants 2D50NS044283-06 [PI}, NIH R01 NS030678 [Co-I], NIH R01 NS 036695 [Co-I], and NIH R01 NS044876 [Co-I).Dr. Wijdicks receives honoraria from Springer for his role as the Editor-in-Chief of Neurocritical Care and receives royalties from books published with Oxford University Press. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..

1) Paraneoplastic isolated myelopathy and 2) Topic of the month: Unusual headache syndromes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Drs. Erik Ensrud and Isabel Arrilaga-Romany interviews Dr. Sean Pittock about his paper on paraneoplastic isolated myelopathy. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about oy-sters in psychogenic non-epileptic seizure diagnosis. In the next part of the podcast Dr. Noah Kolb interviews Dr. Michael Sowell about secondary headaches to conclude this month's theme about unusual headache syndromes. The participants had nothing to disclose except Drs. Pittock and Clardy.Dr. Pittock may accrue revenue for patents re: aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica and aquaporin-4 autoantibody as a cancer marker; and has received research support from Alexion Pharmaceuticals, Inc. and the Guthy Jackson Charitable Foundation.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Etiological investigation of ischemic stroke and 2) Topic of the month: Unusual headache syndromes. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Vincent Larrue about his paper on etiological investigation of ischemic stroke. In the next segment, Dr. Stacy Clardy is reading our e-Pearl of the week about clinical signs of psychogenic non-epileptic seizures. In the next part of the podcast Dr. Michael Levy interviews Dr. Todd Rozen about trigeminal autonomic cephalgia. Next week you will hear our last interview for this month on unusual headache syndromes. The participants had nothing to disclose except Drs. Larrue, Song Levy and Rozen.Dr. Larrue has received funding for travel from Boehringer Ingelheim and received research support from sanofi-aventis.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Levy receives research support from ApoPharma Inc. and Guthy-Jackson Foundation and is funded by the NIH Loan Repayment Grant.Dr. Rozen serves on the speakers' bureau of Merck Serono.